This research develops targeted radiopharmaceutical therapies for HER2-positive cancers. By attaching radioactive isotopes to trastuzumab, treatment delivers precise radiation to cancer cells, overcoming drug resistance. The work includes creating practical drug kits and aims to improve cancer outcomes by replacing non-specific therapies with highly accurate, targeted interventions.

Low-grade serous ovarian cancer frequently returns after standard treatment, and current targeted drugs eventually stop working. This research investigates why cancer cells become resistant, comparing them to prey that adapt to evade a predator. By treating patient-derived tumor cells with inhibitors and analyzing the genes activated in the resistant survivors, the research aims to uncover the mechanisms behind drug resistance and guide development of more effective therapies.